340B and Pharmaceutical Access
The 340B Drug Pricing Program supports safety net providers, such as children's hospitals, in their mission to serve low-income, uninsured and under-insured patients.
Resources for IV Fluid Mitigation
CHA is sharing information from children’s hospitals and industry experts to help address IV fluid disruption in the wake of Hurricane Helene.
CHA Submits Letter to HHS on Baxter Closure
The letter thanks HHS for their response to supply shortages caused by Hurricane Helene and urges continued support for pediatric needs during ongoing IV solution shortages.
High-Cost Therapies for Pediatrics
Pediatric HCTs are innovative and lifesaving or life-altering treatments for children with chronic, rare, and complex conditions.
Summary of Laboratory Developed Tests Final Rule
Children's Hospital Association sent a letter to Energy and Commerce leaders supporting pediatric-focused legislation included in a recent markup.
CHA Submits Energy and Commerce Committee Statement on Oversight of the 340B Drug Pricing Program
Children's Hospital Association urges the committee to work with provider stakeholders to enhance the effectiveness and integrity of the program for children's health.
Addressing Pediatric Drug and Supply Shortages
Children’s hospitals depend on a reliable and safe drug and supply chain to provide life-saving treatments to their pediatric patients.
CHA Comments on Stimulant Medication Shortages
Children’s health groups are asking HHS and the DEA to convene stakeholders to identify actionable solutions about ongoing stimulant medication shortages.
CHA Responds to 340B Draft Bill and Request for Information
The 340B program supports children’s hospitals in their mission to serve low-income and underinsured children regardless of their insurance status.
CHA Response to Drug Shortages White Paper
CHA submitted comments on a drug shortages white paper to highlight pediatric health care needs.
For the Record
View CHA communications to federal policymakers such as statements for the record, RFI responses, regulatory comment letters and more.
